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Research
AbstrACt
Objectives To explore differences in experiences of care 
reported in the Cancer Patient Experience Survey (CPES) 
between patients with cancer of unknown primary (CUP) 
and those with metastatic disease of known primary 
(non-CUP); to determine insights pertaining to the 
experiences of care for CUP respondents from free-text 
comments.
Design Two separate, but related, studies, involving 
secondary analysis of existing data. Using frequency 
matching of CUP and non-CUP patients, statistical 
comparisons of responses to CPES questions were 
conducted. Free-text comments from CUP respondents 
were analysed thematically.
setting and participants The CPES questionnaire 
comprises 63 closed questions measuring 8 areas that 
relate to experience of care and 3 free-text questions. 
Questionnaires were mailed to all adult patients (aged 
≥16 years) in England with cancer admitted to hospital 
between 1 September 2013 and 30 November 2013.
results Matched analysis of closed response items from 
2992 patients found significant differences between CUP 
(n=1496) and non-CUP patients (n=1496): CUP patients 
were more likely to want more written information 
about their type of cancer and tests received, to receive 
their diagnosis from a general practitioner (GP) and 
have seen allied health professionals, but less likely to 
have understood explanations of their condition or had 
surgery. Freetext responses (n=3055) were coded into 17 
categories and provided deeper insight regarding patient 
information and interactions with GPs. CPES data may 
include a preponderance of patients with favourable CUP 
subtypes and patients initially identified as CUP but whose 
primary was subsequently identified.
Conclusions These are the first large-scale studies 
to explore the experiences of care of CUP patients. 
The significant differences identified between the 
experiences of CUP and non-CUP patients suggest CUP 
patients require more psychosocial support and specific 
interventions to manage diagnostic uncertainty and 
the multiple investigations many CUP patients face. 
Substantial limitations were identified with the CPES data, 
emphasising the need for prospective studies.
IntrODuCtIOn
Patients with cancer of unknown primary 
(CUP) have metastatic malignant disease, 
for which an identifiable primary site has not 
been identified after extensive clinical evalu-
ation. CUP is not a single disease, but rather 
a heterogeneous collection of cancer types 
with a wide variety of clinical presentations, 
which are hypothesised to share a common 
tendency to metastasise early.1 CUP was the 
fifth most common cancer in the UK in 2014, 
accounting for 3% of new cancers and 6% of 
cancer deaths.2 Worldwide it has been iden-
tified as between the sixth to eighth most 
common cancer, accounting for 2.3%–5% 
strengths and limitations of this study
 ► The first large-scale study quantifying experiences 
of Cancer of Unknown Primary  (CUP) patients 
compared with those with known primary cancers;
 ► The first qualitative analysis of free-text comments 
drawn from a national sample of CUP patients;
 ► The profile of CUP patients who responded to the 
Cancer Patient Experience Survey were found not to 
be representative of this patient population;
 ► Reasons for sample limitations include: time between 
patient identification and survey participation; 
inconsistent administration of International 
Classification of Diseases 10th Revision codes; 
neglect of CUP typology;
 ► These limitations highlight the need for prospective, 
observational cohort studies to investigate the 
experiential, informational and psychosocial issues 
faced by CUP patients.
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of all new cancer cases and is the third to fourth most 
common cause of death.3 4 The UK National Institute of 
Clinical Excellence (NICE) published guidelines for the 
management of CUP patients in 2010,5 which for the first 
time developed a taxonomy of definitions that reflected 
different phases of investigations for CUP: malignancy 
of undefined primary origin (MUO); provisional CUP 
(pCUP) and confirmed CUP (table 1). The guidelines 
also recommended the establishment of specialist CUP 
multidisciplinary teams (MDTs) in each National Health 
Service (NHS) cancer centre to include an oncologist, 
palliative care physician and clinical nurse specialist.5
However, with the exception of three previous studies,6–8 
there is very little published research on quality of life 
(QoL) and psychosocial aspects of CUP. Patients with 
CUP struggle with uncertainty and distress, especially 
regarding prognosis,6 possible recurrence and the prima-
ry's hereditary potential.7 Problems with care continuity 
commonly faced by cancer patients were amplified for 
those with CUP, particularly in relation to coordination, 
accountability and timeliness of care.7 A recent cross-sec-
tional study from Greece, using matched-sample analysis, 
found patients with CUP experienced higher depression 
and anxiety and poorer QoL compared with those who 
have metastatic disease of either breast or colorectal 
cancer.8
These findings suggest CUP patients may have unique 
psychosocial and supportive care needs, which require 
development of targeted supportive care interventions. 
Internationally, routine assessments of patient experi-
ences of care are used increasingly to drive service quality 
improvements.9 10 In the UK, the NHS Cancer Reform 
Strategy,11 Outcomes Strategy for Cancer12 and recent 
Cancer Taskforce13 documents highlight the important 
role of patient experiences in measuring and improving 
clinical quality. The national Cancer Patient Experience 
Survey (CPES) is an extensive, UK-wide programme of 
research about cancer patients’ experiences of care while 
undergoing inpatient or day-case treatment.14 The CPES 
has been administered annually since 2010 and is the 
biggest survey programme of its kind in the world. The 
data are a public resource and available from the survey 
provider, Quality Health. This represented an opportu-
nity to interrogate these data to understand CUP patients’ 
experiences of care to underpin the development of 
targeted care interventions for this population.
Drawing from the 2013 CPES, this paper reports find-
ings from two related studies: qualitative and quantita-
tive. The aim of both studies was to better understand the 
experiences of care among CUP patients. The quantitative 
study described perceived experiences of care of patients 
diagnosed with CUP compared with patients with meta-
static cancer of a comparable known primary (non-CUP). 
The second, qualitative study analysed free-text responses 
of CUP patients in the CPES to identify emerging themes 
and insights regarding their experiences of cancer care.
MethODs
survey design
The two studies reported here consist of secondary anal-
yses of data collected as part of the English 2013 CPES, 
to assess differences in responses between CUP and 
non-CUP patients and to explore freetext responses of 
patients with CUP.
The 2013 CPES was administered by the survey 
provider, Quality Health. The CPES questionnaire was 
mailed to all adult patients (aged ≥16 years) in England 
with a diagnosis of cancer, who had been admitted to an 
NHS hospital as an inpatient or day case patient over a 
3-month period (1 September 2013–30 November 2013). 
Non-responders were sent one reminder letter and a 
further reminder letter with questionnaire if necessary. 
The overall response rate for the 2013 CPES was 64% 
(n=68 737).14
survey instrument
The CPES instrument contained 63 closed question 
items, measuring eight key areas of patient experience 
across the care trajectory from diagnosis to leaving 
hospital: access to care; respect for patients’ preferences; 
information and education; physical comfort; emotional 
support; involvement of family and friends; continuity 
and transition and coordination of care. Three freetext 
comment boxes at the end of the questionnaire asked the 
following questions: Was there anything particularly good 
about your NHS care? Was there anything that could be 
improved? Any other comments?
Identification of respondents
All NHS hospitals treating adult patients with cancer in 
England were included. Patients were identified from 
data provided by these organisation, selected from local 
patient administration systems. Patients were identi-
fied as CUP using the 10 revision of the International 
Table 1 Terms used in NICE guideline to define CUP
MUO Metastatic malignancy identified on 
the basis of a limited number of tests, 
without an obvious primary site, before 
comprehensive investigation
Provisional 
CUP origin 
Metastatic epithelial or neuroendocrine 
malignancy identified on the basis of the 
histology or cytology, with no primary 
site detected despite a selected initial 
screen of investigations, before specialist 
review and possible further specialised 
investigations
Confirmed CUP 
origin
Metastatic epithelial or neuroendocrine 
malignancy identified on the basis of final 
histology, with no primary site detected 
despite a selected initial screen of 
investigations, specialist review and further 
specialised investigations as appropriate
CUP, cancer of unknown primary; MUO, malignancy of undefined 
primary origin; NICE, National Institute of Clinical Excellence.
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Statistical Classification of Diseases and Related Problems 
(ICD-10) codes: C77 (secondary and unspecified malig-
nant neoplasm of lymph nodes), C78 (secondary malig-
nant neoplasm of respiratory and digestive organs), C79 
(secondary malignant neoplasm of other and unspecified 
sites) and C80 (malignant neoplasm, without specifica-
tion of site).15
AnAlysIs
Frequency matching analysis: matching procedure
A frequency matching analysis was conducted to compare 
responses to the closed survey questions between CUP 
and non-CUP respondents. CPES (2013) respondents 
of 4535 were identified as CUP patients. The original 
plan was to match CUP and non-CUP samples for anal-
ysis on three variables: age group in deciles, sex and type 
of admission (ordinary admission, day case admission 
or regular day case admission). After exploration of the 
data, two further variables needed to be accounted for: 
tumour type and time since treatment start. Prevalence 
of breast and prostate cancer were high among non-CUP 
respondents to the CPES questionnaire, and it seemed 
inappropriate to match the CUP sample against a high 
proportion of such patients given estimates of likely 
site of origin in CUP cases from autopsy and biomarker 
studies.16 For this reason, the dataset was restricted so 
these two tumour types represented only 5% each in the 
known primary sample. Preliminary analysis also found 
a marked difference between the CUP and non-CUP 
respondents regarding time since commencing cancer 
treatment (figure 1). Patients with CUP were found 
disproportionally to have commenced treatment >1 year 
prior to the survey (34% of CUP vs 73% of non-CUP); 
many more than would normally be expected among a 
random CUP sample and suggests a high proportion of 
favourable CUP subtypes.4 Due to the small proportion of 
non-CUP patients who responded that it had been longer 
than 1 year since they began treatment, it was impossible 
to match on this variable, so the sample was restricted to 
only those patients who responded ‘less than 1 year’.
The final sample included 1496 CUP patients who 
began treatment in the past year, with no missing data 
on the matching variables (age, sex and administration 
type). All patients were assigned identification and CUP 
patients were matched with randomly selected non-CUP 
patients, who had no missing data on the matching vari-
ables, began treatment in the past year and were diag-
nosed with metastatic disease in specific tumour types 
(colorectal, breast, head and neck, kidney/adrenal, pros-
tate, pancreas and upper and lower gastrointestinal). 
These sites were selected as the primary sites from which 
CUP is most commonly thought to arise.16 The final 
combined dataset contained 2992 respondents (table 2).
Frequency matching analysis: analysis
χ2 tests assessed associations between diagnosis type 
(CUP vs non-CUP) and responses to each item. Given the 
very large sample, the likelihood of finding statistically 
significant associations at p<0.05 was high. It was there-
fore determined a priori that a ‘small’ or greater effect 
would be classified as meaningful; this corresponds to a 
Cramer’s V of greater than 0.1 for comparisons where the 
degrees of freedom (df)=1, 0.07, where df=2, 0.06, where 
df=3,0.05 and where df=4 or 5.17
Free-text analysis
Free-text responses provided by patients diagnosed with 
CUP were analysed to provide insights into their experi-
ences of care. Comments were extracted from the CPES 
data set as individual text files and loaded into the NVivo 
qualitative data analysis software package. A coding 
framework for sorting free-text data from a previous study 
of responses to the Welsh CPES 2013 (WCPES)18 was 
Figure 1 Percentage of CUP and non-CUP cases for each response category (Q76). CUP, cancer of unknown primary.
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used. A sample of 200 randomly selected comments were 
double coded by two researchers (MB, RW) to ensure 
compatibility of the framework. Coding agreement 
between the two researchers was 80% (Cohen’s Kappa). 
Any conflicts were resolved through discussion between 
coders. The framework was then used to categorise the 
free-text comments. Search criteria were developed for 
each category, using terms gleaned from term frequency 
and unique terms analyses of the coded data from the 
WCPES study. The search strategy was designed to identify 
relevant comments for each theme. During this process, 
all comments were read and coded. Following categori-
sation of comments, a second level of thematic analysis 
was conducted on specific free-text categories to provide 
greater depth of insight.19
ethics and data management
CPES data is a public resource and available from the 
survey provider, Quality Health. Data were anonymised 
and secondary analysis of closed questions permitted with 
agreement from NHS England. Because free-text data may 
contain personal identifiable data, approval from NHS 
England to analyse CPES free-text data was separately 
secured. Free-text analysis of CPES data was approved 
by the University of Southampton Ethics Committee on 
12 November 2014 (UoS Ethics ID:12313).
FInDIngs
The demographic and clinical characteristics of respon-
dents in both the matched analysis and free-text samples 
are shown in table 2. The mean age of samples were 
similar; 65.3 for the CUP free-text sample, 66.5 and 
66.6, respectively, for the matched CUP and non-CUP 
samples. Matched samples contained equal numbers of 
men (39%, n=583) and women (61%, n=913), propor-
tions were broadly similar for the free-text sample (36.7% 
(n=1121) and 63.3% (n=1934), respectively). Finally, the 
ICD-10 codes of respondents indicated c78 (33%, n=496) 
as the largest categorisation in the CUP matched sample 
and c79 (39.6%, n=1209) the largest in the free-text 
sample, while c80 was the smallest categorisation for both 
samples; 11% (n=166) and 5.2% (n=160), respectively.
Patient experiences: closed responses
Sixty comparisons were conducted. Of these, nine items 
showed differences between the CUP and non-CUP 
respondents that were classified as meaningfully different 
(table 3). In response to question 8 (‘Beforehand, were 
you given written information about your (diagnostic) 
tests?’), CUP patients were more likely to respond ‘No, 
but I would have liked written information about the 
test/s’ or ‘I did not need written information’ and less 
likely to respond ‘Yes, and it was easy to understand’. 
Table 2 Demographic and clinical characteristics of the sample are shown in table 2
Observation Free-text sample (n=3055)
Marched-pair samples (2992)
CUP (n=1496) Non-CUP (n=1496)
Age
  Mean (SD) 65.3 (11.3) 66.5 (11.7) 66.6 (11.5)
  Median (IQR) 66 (58, 73) 67 (59, 75) 67 (59, 75)
  Range 16, 95 20, 98 23, 94
  Sex n % n % n %
  Male 1121 36.7 583 39.0 583 39.0
  Female 1934 63.3 913 61.0 913 61.0
Diagnosis
  CUP 3055 100 1496 100 –
  Breast – 111 7.4
  Head and neck – 185 12.4
  Lung – 271 18.1
  Pancreatic – 44 2.9
  Prostate – 52 3.5
  Renal – 89 5.9
  Upper and lower GI – 744 49.7
ICD-10 codes
  C77 514 16.8 399 27 – –
  C78 1172 38.4 496 33 – –
  C79 1209 39.6 435 29 – –
  C80 160 5.2 166 11 – –
CUP, cancer of unknown primary; ICD-10, International Classification of Diseases 10th Revision.
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Table 3 Matched paired analysis: CUP and non-CUP patients
Item
CUP
n (%)
Known primary n 
(%) Cramer's V
Q8. Beforehand, were you given written information about your test(s)?
  Yes, and it was easy to understand 808 (83) 917 (90) 0.102
  Yes, but it was difficult to understand 37 (4) 32 (3)
  No, but I would have liked written information about the test(s) 127 (13) 73 (7)
  I did not need written information/Don’t know/can’t remember 392 334
Q9. Were the results of the test(s) explained to you in a way you could understand?
  Yes, completely 961 (72) 1042 (78) 0.076
  Yes, to some extent 322 (24) 259 (20)
  No, but I would have liked an explanation 48 (4) 28 (2)
  I did not need an explanation/Don't know/can't remember/Missing 33 27
Q10. Who first told you that you had cancer?
  A hospital doctor 1191 (81) 1199 (82) 0.104
  A hospital nurse 44 (3) 91 (6)
  A GP 155 (11) 104 (7)
  Another health professional 40 (3) 51 (4)
  A friend or relative 5 (0.3) 3 (0.2)
  Nobody—I worked it out for myself 30 (2) 17 (1)
  Missing 31 31
Q13. Did you understand the explanation of what was wrong with you?
  Yes, I completely understood it 1006 (68) 1162 (78) 0.123
  Yes, I understood some of it 438 (30) 313 (21)
  No, I did not understand it 32 (2) 9 (1)
  Can’t remember/Missing 20 12
Q14. When you were told you had cancer, were you given written information about the type of cancer you had?
  Yes, and it was easy to understand 670 (54) 834 (67) 0.132
  Yes, but it was difficult to understand 104 (8) 91 (7)
  No, I was not given written information about the type of cancer I had 466 (38) 326 (26)
  I did not need written information/Don't know/can't remember/Missing 256 245
Q16. Do you think your views were taken into account when the team of doctors and nurses caring for you were discussing 
which treatment you should have?
  Yes, definitely 848 (61) 951 (68) 0.078
  Yes, to some extent 343 (25) 284 (20)
  No, my views were not taken into account 112 (8) 82 (6)
  I didn't know my treatment was being discussed by a team of doctors/
nurses
91 (7) 80 (6)
  Not sure/can't remember/Missing 102 99
Q32. During the last 12 months, have you had an operation (such as removal of a tumour or lump) at one of the hospitals in the 
covering letter?
  Yes 824 (55) 1004 (67) 0.124
  No 635 (42) 469 (31)
  Missing 37 23
Q34. Beforehand, were you given written information about your operation?
  Yes, and it was easy to understand 472 (64) 649 (71) 0.077
  Yes, but it was difficult to understand 36 (5) 30 (3)
  No, I was not given written information about my operation 229 (31) 234 (26)
Continued
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Similarly, Q9 ‘Were the results of your tests explained to 
you in a way you could understand?’, CUP patients were 
less likely to respond ‘Yes, completely’. In response to 
Q10 (‘Who first told you that you had cancer?’), CUP 
participants were more likely to respond ‘A GP’ and less 
likely to respond ‘A hospital nurse’, with similar propor-
tions indicating ‘a hospital doctor’. In relation to Q13 
(‘Did you understand the explanation of what was wrong 
with you?’), CUP patients were less likely to answer ‘Yes, 
I completely understood it’ and more likely to respond 
‘Yes, I understood some of it’ or ‘No, I did not understand 
it’. For Q14 (When you were told you had cancer, were 
you given written information about the type of cancer 
you had?), CUP patients were less likely to respond ‘Yes, 
and it was easy to understand’ and more likely to respond 
‘No, I was not given written information about the type 
of cancer I had’. In response to Q16 ‘Do you think your 
views were taken into account when the team of doctors 
and nurses caring for you were discussing which treat-
ment you should have?’, CUP patients were less likely to 
answer ‘Yes, definitely’. CUP patients were less likely to 
report having had surgery in the past 12 months (Q32), 
and in response to Q34 ‘Beforehand, were you given 
written information about your operation?’, were less 
likely to respond ‘Yes, and it was easy to understand’ and 
more likely to respond ‘No, I was not given written infor-
mation about my operation’. Finally, CUP patients were 
more likely to report having received treatment from a 
lymphoedema specialist (Q66).
Patient experiences: free text
3055 CUP patients provided comments to one or more 
of the three free-text questions. The mean length of 
comments was 64.2 words, with female respondents 
providing longer comments than male respondents (54.2 
words and 69.9 words, respectively). Comments were 
retrieved from the dataset for 17 categories (table 4). 
Positive comments were predominant in eight cate-
gories (‘communication with patients’, ‘consultants’, 
‘nursing’, ‘clinical nurse specialists’, ‘chemotherapy’, 
‘radiotherapy’, ‘surgery’ and ‘palliative care’). Predomi-
nantly, negative comments were provided by participants 
for the remaining nine categories (‘interagency commu-
nication’, ‘waiting for appointments/investigations’, 
‘waiting on the day’, ‘receiving results of investigations’, 
‘GPs’, ‘accident and emergency’, ‘emotional, social and 
psychological needs’, ‘financial concerns’ and post-treat-
ment care’). Ratios of negative to positive comments 
varied widely between categories, with the greatest 
proportion of negative comments reported for ‘waiting 
time on the day’, while the greatest proportion of posi-
tive comments was for ‘palliative care’ (though numbers 
were small). A trend existed within all themes that posi-
tive comments tended to be of a more general quality and 
scope than negative comments. Essentially, if participants 
were reporting a negative experience they provided more 
detail.
Three of the nine closed questions for which responses 
between CUP and non-CUP patients showed significant 
differences (Q10, Q13 and Q14) broadly mapped against 
particular free-text categories. Comments in these cate-
gories were subsequently thematically analysed in greater 
depth.
Patient information support from health professionals
When investigated further, comments pertaining to 
–patient information (n=310) provided insights on 
patient responses to the closed questions 9, 13, 14 and 
34; whether patients understood explanations given of 
their condition or their test results and whether they 
were provided with sufficient written information about 
their cancer or tests received. This free-text category 
had a net ratio of positive comments (0.4:1), but several 
themes were identified among negative comments 
(n=89) that indicated why patients found explanations 
of their condition difficult to understand and why they 
needed more information. For example, one CUP 
patient related her difficulty understanding why clini-
cians were unable to locate the primary tumour site, 
despite several investigations:
I had two liver biopsies (the first one did not have 
sufficient to discern whether benign or malignant). 
I had a scan while in hospital, also a CT scan and 
an MRI scan. On my discharge, I later received an 
appointment for an endoscopy when two small 
nodules were discovered in the gullet, a biopsy was 
taken – they were benign, the tumour on the liver 
is a secondary and they still do not know where the 
primary is. (Female, 64 years)
Patients were therefore sometimes uncertain or 
confused with regards the type of cancer they had and 
Item
CUP
n (%)
Known primary n 
(%) Cramer's V
  Don't know/can't remember/Missing 87 91
Q66. Have you had treatment from any of the following (cancer specialists) for your cancer (patients were asked to tick as 
many as apply from the following list: physiotherapist; occupational therapist; dietician; speech and language therapist; 
lymphoedema specialist)
  Yes 132 (9) 37 (3) 0.138
CUP, cancer of unknown primary.
Table 3 Continued 
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alluded to the frustration of not knowing and fears of 
progression:
Further detailed information of my cancer needed. 
Exactly where secondaries are and what kind of 
problems they could cause. Not knowing can be 
most distressing as you try to second guess things too 
much. (Female, 72 years)
They cannot find the primary source so it is rather 
upsetting as to how the disease is progressing. (Male, 
69 years)
Some patients wished to receive more information 
about what to expect from the diagnosis, but moreover, 
wanted an opportunity to discuss what this meant for 
them:
I would have liked to have had information about 
how my type of cancer usually progresses, plus a care 
plan for my own case. I would have liked to have had 
a chat, as a matter of course, to someone about the 
practical side of having cancer. (Male, 71 years)
Nevertheless, despite receiving explanations of their 
conditions from health professionals, patients sometimes 
reported difficulties with understanding the terminology 
used:
The surgeon I see cannot explain things without 
using clinical terms I do not understand. He could if 
he tried! And so often I do not understand the detail. 
In addition he is relatively emotionless. (Female, 57 
years)
In addition, patients sometimes reported receiving 
conflicting information from the many doctors involved 
in their care:
Sometimes difficult to get answers as too many doctors 
and nurses dealing with me and not passing on the 
relevant information and then having to explain it all 
over again. (This happened many times.) (Male, 68 
years)
Several clinicians could be involved with a CUP 
patient’s care, leading to conflicting information, as they 
were sometimes passed between clinical teams, as this 
comment suggests:
The only thing that could be improved was because 
it was a process of elimination I went from chest 
Table 4 Comment categories with counts and ratios of positive and negative comments
Comment category
Negative 
comments (n=)
Positive 
comments (n=)
Negative to 
positive ratio (n: 1)
Overall ratio
(+ve/–ve)
CUP dataset 
coverage (%)
1. Cross cutting themes
  Interagency communication 351 139 2.38 -ve 15.3
  Patient information 89 221 0.40 +ve 10.4
  Waiting for appointments/
investigations
88 72 1.24 -ve 5.2
  Waiting on the day 299 12 24.9 -ve 10.2
  Investigations—receiving results 165 37 4.46 -ve 6.32
2. Healthcare professionals
  GPs 220 91 2.41 -ve 6.32
  Consultants 49 98 0.50 +ve 4.8
  Nursing 284 409 0.69 +ve 22.7
  Clinical nurse specialists 28 72 0.39 +ve 3.3
3. Treatment specialisms
  Accident and emergency 28 12 2.33 -ve 1.3
  Chemotherapy 58 282 0.21 +ve 11.1
  Radiotherapy 32 81 0.39 +ve 3.7
  Surgery 170 350 0.49 +ve 17.0
  Palliative care 2 40 0.05 +ve 1.3
  Post-treatment care 38 32 1.19 -ve 2.3
4. Other quality of life concerns
  Emotional, social and psychological 
needs
39 17 2.29 -ve 1.3
  Financial concern 75 7 10.71 -ve 2.7
CUP, cancer of unknown primary; GPs, general practitioners.
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specialist, to organ oncologist and after my scans and 
biopsies finally back to my breast oncologist of 11 
years ago. So my treatment didn’t’ start until end of 
March—6 months later. (Female, 62 years)
gPs’ diagnosis of CuP
Analysis of closed items indicated CUP patients were 
more likely than non-CUP patients to be given their diag-
nosis by a GP. Analysis of comments regarding interac-
tions with GPs (n-311) provided by participants found 
CUP patients were more likely to report negative rather 
than positive experiences with GPs (ratio of 2.4:1). The 
theme containing most comments concerning GPs 
related to speed of diagnosis/referral for further investi-
gations. Negative comments often indicated months and 
sometimes years of consulting GP services with cancer 
symptoms before diagnosis and/or specialist referral was 
made:
I wish my original GP had listened properly over 
the months I complained about weight loss (over 
two stone). Instead I had to change my GP who 
fast tracked me into hospital where a scan showed 
metastasized tumours. (Female, 81 years)
Comments often related delayed referrals as a conse-
quence of GPs attributing symptoms to conditions other 
than cancer or giving insufficient regard to previous 
cancer diagnoses. Some comments described ‘misdiag-
nosis’ of symptoms were later found to be inaccurate.
Very upset that I have to call the GP, a couple of times 
a week for 5 weeks, my pain getting worse by the day. 
My wife asked on a couple of visits if I could have 
x-ray, blood tests, GP said nothing wrong with me, it 
was just back ache. In the end my wife took me to 
A&E. She had to get me into wheelchair from the car. 
I was in terrible pain. (Male, 79 years)
Poor communication between GP and secondary 
care services was also a prevalent topic within the ‘GP’ 
category and revealed a lack of continuity between GP 
and secondary care. It is important to note that these 
comments were often not critical of GP services but of 
the information provided to them by secondary services.
I should like my GP to be kept informed more 
quickly of my treatment at hospital. At the moment, 
information does not get to her quickly enough, so 
if I want to discuss something with her, she does not 
have up to date information, sometimes 3–4 weeks 
behind. (Female, 65 years)
DIsCussIOn
To our knowledge, these two investigations represent the 
first, large-scale studies quantifying the experiences of 
people with CUP compared with people with metastatic 
known primary cancers and the first qualitative analysis 
of free-text comments from participants drawn from a 
national sample of CUP patients. Experiences of patients 
with CUP were broadly similar to those with advanced 
metastatic cancer, with the exception of the nine areas 
reported. This might suggest the success of recommen-
dations advocated by NICE in the UK that relate to the 
introduction of MDTs and specialist nurses dedicated 
to patients with CUP,5 and that equivalent standards of 
care now exist irrespective of whether the primary site 
was known or unknown. However, it is not yet clear how 
consistently CUP MDTs have been established across the 
UK, and it is doubtful they were well established by 2013.
Patients in the CUP sample were significantly more 
likely to answer they would have liked more information 
than the non-CUP sample about the type of cancer they 
had and the investigations they underwent and signifi-
cantly less likely to understand the explanations of what 
was wrong with them. Providing accurate and helpful 
information and preparing CUP patients for their treat-
ment trajectory is especially difficult given the uncer-
tainty that pervades this diagnosis. The location of the 
primary tumour is the main reference point for treatment 
decisions and prognostic information,20 treatment regi-
mens may change several times during a patient’s illness 
trajectory and patients often receive conflicting infor-
mation from clinicians.7 Doctors face challenges when 
communicating with CUP patients in the face of such 
uncertainty,20 21 and consequently doctors often experi-
ence discomfort.22 CUP patients also frequently undergo 
a greater number of investigations than patients with a 
known primary, as clinicians sometimes inappropriately 
‘chase the primary’.23 Many doctors prefer to estimate a 
primary site on the basis of clinical signs but there is little 
consistency in the language used to describe the diagnosis 
to patients.21 The number and diversity of health profes-
sionals involved with their care is often greater for CUP 
than non-CUP patients as they are often reviewed and 
moved between multidisciplinary clinical teams.7 This 
can result in confusion and anxiety for patients,6 7 and 
may partly explain why CUP patients reportedly felt their 
views were less often taken into account during treatment 
decision-making.
CUP patients were significantly more likely to be first 
told by their GP that they had cancer, compared with 
the non-CUP sample. It may be that, as CUP patients are 
often not adopted by a specific MDT or are ‘bounced’ 
between MDTs,7 24 GPs may take responsibility for relaying 
the diagnosis to the patient on the basis of accumulating 
evidence, possibly prior to referring them to specialist 
consultation. Nevertheless, free-text responses also found 
CUP patients were more likely to report negative rather 
than positive experiences of interactions with GPs (ratio 
of 2.4:1), which often related to referrals being delayed 
as a consequence of GPs attributing symptoms to condi-
tions other than cancer or not sufficiently investigating 
patients’ health concerns. That referral systems for MUO 
from primary to secondary care is variable across the UK 
may also contribute to such delays. CUP patients were 
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significantly less likely to have surgery; by definition, 
patients with CUP are diagnosed after a primary has 
metastasised and hence surgery is not usually an option. 
In contrast, those patients with an advanced known 
primary may well have had surgery prior to the discovery 
of metastases. Finally, the finding that patients with CUP 
are more likely to have seen a lymphoedema specialist is 
difficult to explain and may be an artefact of the limita-
tions of the sample as discussed below.
A major limitation of this study is that the CUP sample 
is not representative of the profile of patients with CUP. 
During 2006–2010, the 1-year relative survival for CUP 
patients in the UK was 16%,25 yet in this sample 62% of 
respondents with CUP had begun treatment for their 
cancer more than 1 year previous to their diagnosis. Poten-
tially, many of the patients in the CUP sample may have a 
favourable subtype of CUP: those with likely primary sites 
that have greater survival rates and reliable treatments,4 
who may be still receiving follow-up care at hospital in the 
years that followed their original diagnosis. We attempted 
to control for this potential bias by restricting the CUP 
sample to those who were first treated for their cancer less 
than 1 year previously. Nevertheless, these people were 
still well enough to complete the CPES several months 
postdischarge. Speculatively, the CUP sample in this 
analysis may be more like patients with advanced known 
cancer than a CUP sample recruited prospectively after 
diagnosis of confirmed CUP, which would have included 
many more individuals with poorer prognoses. Indeed, 
while almost half (49%) of patients diagnosed with CUP 
in 2009 were coded to the ICD-10 code C80, which also 
accounted for 93% of deaths from CUP in 2010,26 a much 
smaller proportion of patients coded C80 were included 
in the CPES CUP population sample. Therefore, a 
prospectively recruited sample of CUP patients might 
have less positive experiences than the CUP sample in this 
analysis. Moreover, as we selected patients with a known 
primary for the non-CUP sample to approximate propor-
tions of likely site of origin in CUP cases from autopsy 
and biomarker studies,16 we have enriched the non-CUP 
sample with patients who have poorer prognoses, such as 
those with pancreatic and lung cancers. These patients 
may have less positive experiences than a more omnibus 
sample of patients with advanced known primaries.
Compounding these issues, the diagnoses used in this 
study were not self-reported or clinician reported but 
based on administrative data. The ICD-10 classification 
system does not differentiate between MUO, pCUP and 
cCUP.5 For CPES, the ICD code was extracted directly 
from each Trust’s administrative data records, and two 
errors may subsequently occur with this method. First, as 
ICD codes are generated by MDT administrators and not 
by doctors, there may be errors in coding. The second, 
more serious issue is that because no distinction is made 
in the data capture between MUO, pCUP and cCUP, it is 
possible that if a primary site is later confirmed the coding 
will not be updated in the administrative file. As the survey 
maybe completed by patients some months postdiagnosis, 
some patients within our CUP sample may have already 
received a site-specific diagnosis, and the sample is there-
fore not fully representative of the profile of patients with 
MUO/CUP. Errors in classifying CUP are likely to be more 
pronounced for the CUP sample due to the uncertainty of 
whether or when a primary might be found and because 
patients with MUO can pass among several multidisci-
plinary teams managing different cancer types.7 Finally, 
using administrative data to define the CUP sample 
also fails to account for the patient’s perception of their 
disease. Indeed, the limited research that exists indicates 
that patients are often very confused about a diagnosis 
of CUP and for many patients clinicians convey a ‘best 
guess’ primary site to direct treatment or access subsidised 
medical therapy.21 What and how they are told of their 
diagnosis may influence their questionnaire responses.
COnClusIOn
These findings, when combined, suggest CUP patients 
may experience delays in diagnosis and to specialist 
referral and greater uncertainty with regards under-
standing their diagnosis and be less prepared for what to 
expect regarding diagnostic investigations than patients 
with a known primary site. These represent specific areas 
where targeted psychoeducational interventions might 
be developed. But, given we identified significant limita-
tions with the CPES CUP sample data, possibly as a conse-
quence of inconsistent or erroneous coding and neglect 
of the NICE taxonomy of CUP, it is crucial to conduct 
prospective, observational cohort studies to develop a 
more complete understanding of the issues faced by CUP 
patients.
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